title: Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse.
abstract: Even in the era of new drugs, multiple myeloma patients with extramedullary relapse have a poor prognosis. Our goal was to analyze the frequency and outcome of extramedullary relapse occurring in relapsed multiple myeloma patients. In total, we analyzed the prognosis of 226 relapsed multiple myeloma patients treated between 2005 and 2008 and evaluated them for presence of extramedullary relapse. We found evidence of extramedullary relapse in 24% (55 of 226) of relapsed multiple myeloma patients. In 14% (32 of 226) of patients, the lesions were not adjacent to the bone, while extramedullary relapse adjacent to the bone was documented in 10% (23 of 226) of cases. Patients without extramedullary relapse had significantly longer overall survival than patients with extramedullary relapse (109 vs. 38 months; P<0.001). Moreover, patients with soft tissue-related extramedullary relapse had significantly poorer overall survival compared to bone-related extramedullary relapse patients (30 vs. 45 months; P=0.022). Also, overall survival from diagnosis was as low as five months for soft tissue-related extramedullary relapse patients when compared to 12 months overall survival for bone-related extramedullary relapse. This is the first study that shows a significant difference in prognosis for different types of extramedullary relapse. If the extramedullary myeloma infiltration was not bone-related, overall survival after relapse was extremely short (5 months).
authors.affiliation: rom.hajek@seznam.cz.
authors.forename: Ludek
authors.initials: L
authors.lastname: Pour
authors.forename: Sabina
authors.initials: S
authors.lastname: Sevcikova
authors.forename: Henrieta
authors.initials: H
authors.lastname: Greslikova
authors.forename: Renata
authors.initials: R
authors.lastname: Kupska
authors.forename: Petra
authors.initials: P
authors.lastname: Majkova
authors.forename: Lenka
authors.initials: L
authors.lastname: Zahradova
authors.forename: Viera
authors.initials: V
authors.lastname: Sandecka
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Adam
authors.forename: Marta
authors.initials: M
authors.lastname: Krejci
authors.forename: Petr
authors.initials: P
authors.lastname: Kuglik
authors.forename: Roman
authors.initials: R
authors.lastname: Hajek
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000401:mortality / Q000473:pathology / Q000556:secondary; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy; D012189:Retrospective Studies; D012307:Risk Factors; D012983:Soft Tissue Neoplasms / Q000401:mortality / Q000556:secondary / Q000628:therapy; D015996:Survival Rate
references.citation: Eur J Haematol. 2006 May;76(5):405-8
references.pmid: 16529604
references.citation: Eur J Haematol. 2008 Dec;81(6):432-6
references.pmid: 18691254
references.citation: Ann Oncol. 2010 Feb;21(2):325-330
references.pmid: 19633044
references.citation: Hematology Am Soc Hematol Educ Program. 2004;:237-56
references.pmid: 15561686
references.citation: Neoplasma. 2010;57(2):111-7
references.pmid: 20099973
references.citation: Clin Lymphoma Myeloma. 2009 Dec;9(6):436-42
references.pmid: 19951883
references.citation: Onkologie. 2004 Jun;27(3):275-9
references.pmid: 15249717
references.citation: Bone Marrow Transplant. 2004 Dec;34(12):1057-65
references.pmid: 15516937
references.citation: Haematologica. 2007 Jan;92(1):50-5
references.pmid: 17229635
references.citation: Klin Onkol. 2011;24 Suppl:S10-3
references.pmid: 21923057
references.citation: J Clin Oncol. 2010 Jun 20;28(18):3023-7
references.pmid: 20479421
references.citation: Adv Ther. 2011 Nov;28 Suppl 7:1-6
references.pmid: 22105527
references.citation: N Engl J Med. 2003 Jun 26;348(26):2609-17
references.pmid: 12826635
references.citation: N Engl J Med. 2007 Nov 22;357(21):2123-32
references.pmid: 18032762
references.citation: J Clin Oncol. 2011 Oct 1;29(28):3805-12
references.pmid: 21900099
references.citation: Haematologica. 2012 Nov;97(11):1761-7
references.pmid: 22689675
references.citation: Biol Blood Marrow Transplant. 2010 Apr;16(4):548-54
references.pmid: 20005965
references.citation: Leukemia. 2006 Mar;20(3):542-5
references.pmid: 16408097
references.citation: Haematologica. 2002 Jun;87(6):609-14
references.pmid: 12031917
references.citation: Leukemia. 2009 Dec;23(12):2210-21
references.pmid: 19798094
references.citation: Blood. 2012 May 10;119(19):4375-82
references.pmid: 22422823
references.citation: Eur J Haematol. 2005 Nov;75(5):376-83
references.pmid: 16191086
references.citation: Hematology Am Soc Hematol Educ Program. 2005;:373-6
references.pmid: 16304406